This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 2011; 89: 716-24. 10.2471/BLT.11.086678DelgermaaVTakahashiKParkEKLeGVHaraTSorahanT.Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008Bull World Health Organ2011897162410.2471/BLT.11.086678Open DOISearch in Google Scholar
Cancer in Slovenia 2014. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2017.Cancer in Slovenia 2014LjubljanaInstitute of Oncology LjubljanaEpidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia2017Search in Google Scholar
Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52–67. 10.1016/j.cell.2010.03.015KessenbrockKPlaksVWerbZ.Matrix metalloproteinases: regulators of the tumor microenvironmentCell2010141526710.1016/j.cell.2010.03.015Open DOISearch in Google Scholar
Rawlings ND, Barrett AJ. Evolutionary families of metallopeptidases. Methods Enzymol 1995; 248: 183-228.RawlingsNDBarrettAJ.Evolutionary families of metallopeptidasesMethods Enzymol199524818322810.1016/0076-6879(95)48015-3Search in Google Scholar
Mineo TC, Ambrogi V. Malignant pleural mesothelioma: factors influencing the prognosis. Oncology (Williston Park) 2012; 26: 1164-75.MineoTCAmbrogiV.Malignant pleural mesothelioma: factors influencing the prognosisOncology (Williston Park)201226116475Search in Google Scholar
Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2006; 13: 229-37. 10.1245/ASO.2006.03.045DeracoMNonakaDBarattiDCasaliPRosaiJYounanRPrognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusionAnn Surg Oncol2006132293710.1245/ASO.2006.03.04516444562Open DOISearch in Google Scholar
Štrbac D, Goričar K, Dolžan V, Kovač V. Matrix metalloproteinases polymorphisms as prognostic biomarkers in malignant pleural mesothelioma. Dis Markers 2017; 2017: 8069529. Epub 2017 Sep 12. 10.1155/2017/8069529.ŠtrbacDGoričarKDolžanVKovačV.Matrix metalloproteinases polymorphisms as prognostic biomarkers in malignant pleural mesotheliomaDis Markers201720178069529Epub 2017Sep 1210.1155/2017/8069529561336229138529Open DOISearch in Google Scholar
Nan H, Niu T, Hunter DJ, Han J. Missense polymorphisms in matrix metalloproteinase genes and skin cancer risk. Cancer Epidemiol Biomarkers Prev 2008; 17: 3551-7. 10.1158/1055-9965.EPI-08-0606NanHNiuTHunterDJHanJ.Missense polymorphisms in matrix metalloproteinase genes and skin cancer riskCancer Epidemiol Biomarkers Prev2008173551710.1158/1055-9965.EPI-08-0606266462519064570Open DOISearch in Google Scholar
Lin CM, Zeng YL, Xiao M, Mei XQ, Shen LY, Guo MX, et al. The relationship between MMP2 -1306C>T and MMP9 -1562C>T polymorphisms and the risk and prognosis of T-cell acute lymphoblastic leukemia in a Chinese population. Cell Physiol Biochem 2017; 42: 1458-68. 10.1159/000479210LinCMZengYLXiaoMMeiXQShenLYGuoMXThe relationship between MMP2-1306C>T and MMP9 -1562C>T polymorphisms and the risk and prognosis of T-cell acute lymphoblastic leukemia in a Chinese populationCell Physiol Biochem20174214586810.1159/00047921028719899Open DOISearch in Google Scholar
Kovač V, Zwitter M, Štrbac D, Goričar K, Rozman A, Kern I, Rajer M. Cisplatin with pemetrexed or gemcitabine in prolonged infusion for inoperable mesothelioma: a phase II randomized trial. [Abstract]. 17th World Conference on Lung Cancer, 4-7 December 2016, Vienna, Austria. J Thorac Oncol 2017; 12(Suppl 1): S715.KovačVZwitterMŠtrbacDGoričarKRozmanAKernIRajerM.Cisplatin with pemetrexed or gemcitabine in prolonged infusion for inoperable mesothelioma: a phase II randomized trial. [Abstract]. 17th World Conference on Lung Cancer, 4-7 December 2016, Vienna, AustriaJ Thorac Oncol201712Suppl 1S71510.1016/j.jtho.2016.11.1929Search in Google Scholar
National Institute of Environmental health Sciences. SNP Function Prediction (Func Pred). [Internet]. Available at https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.html. Accessed 15 Jan 2017.National Institute of Environmental health SciencesSNP Function Prediction (Func Pred). [Internet]https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htmlAccessed 15 Jan 2017Search in Google Scholar
Wang J, Cai Y. Matrix metalloproteinase 2 polymorphisms and expression in lung cancer: a meta-analysis. Tumour Biol 2012; 33: 1819-28. 10.1007/s13277-012-0441-0WangJCaiY.Matrix metalloproteinase 2 polymorphisms and expression in lung cancer: a meta-analysisTumour Biol20123318192810.1007/s13277-012-0441-022718017Open DOISearch in Google Scholar
Hu C, Wang J, Xu Y, Li X, Chen H, Bunjhoo H, et al. Current evidence on the relationship between five polymorphisms in the matrix metalloproteinases (MMP) gene and lung cancer risk: a meta-analysis. Gene 2013; 517: 65-71. 10.1016/j.gene.2012.12.085HuCWangJXuYLiXChenHBunjhooHCurrent evidence on the relationship between five polymorphisms in the matrix metalloproteinases (MMP) gene and lung cancer risk: a meta-analysisGene2013517657110.1016/j.gene.2012.12.08523313298Open DOISearch in Google Scholar
Tao L, Li Z, Lin L, Lei Y, Hongyuan Y, Hongwei J, et al. MMP1, 2, 3, 7, and 9 gene polymorphisms and urinary cancer risk: a meta-analysis. Genet Test Mol Biomarkers 2015; 19: 548-55. 10.1089/gtmb.2015.0123TaoLLiZLinLLeiYHongyuanYHongweiJMMP1, 2, 3, 7, and 9 gene polymorphisms and urinary cancer risk: a meta-analysisGenet Test Mol Biomarkers2015195485510.1089/gtmb.2015.0123459938926301605Open DOISearch in Google Scholar
Wieczorek E, Reszka E, Jablonowski Z, Jablonska E, Beata Krol M, Grzegorczyk A, et al. Genetic polymorphisms in matrix metalloproteinases (MMPs) and tissue inhibitors of MPs (TIMPs), and bladder cancer susceptibility. BJU Int 2013; 112: 1207-14. 10.1111/bju.12230WieczorekEReszkaEJablonowskiZJablonskaEBeata KrolMGrzegorczykAGenetic polymorphisms in matrix metalloproteinases (MMPs) and tissue inhibitors of MPs (TIMPs), and bladder cancer susceptibilityBJU Int201311212071410.1111/bju.1223023819551Open DOISearch in Google Scholar
Sherry ST, Ward MH, M. Kholodov, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29: 308-11.SherrySTWardMHKholodovM.BakerJPhanLSmigielskiEMdbSNP: the NCBI database of genetic variationNucleic Acids Res2001293081110.1093/nar/29.1.3082978311125122Search in Google Scholar
Tunesi S, Ferrante D, Mirabelli D, Andorno S, Betti M, Fiorito G, et al. Gene-asbestos interaction in malignant pleural mesothelioma susceptibility. Carcinogenesis 2015; 36: 1129-35. 10.1093/carcin/bgv097TunesiSFerranteDMirabelliDAndornoSBettiMFioritoGGene-asbestos interaction in malignant pleural mesothelioma susceptibilityCarcinogenesis20153611293510.1093/carcin/bgv09726139392Open DOISearch in Google Scholar
Franko A, Kotnik N, Goricar K, Kovac V, Dodic-Fikfak M, Dolzan V. The influence of genetic variability on the risk of developing malignant mesothelioma. Radiol Oncol 2018; 52: 105-111. doi: 10.1515/raon-2018-0004FrankoAKotnikNGoricarKKovacVDodic-FikfakMDolzanV.The influence of genetic variability on the risk of developing malignant mesotheliomaRadiol Oncol20185210511110.1515/raon-2018-0004Open DOISearch in Google Scholar
Neri M, Filiberti R, Taioli E, Garte S, Paracchini V, Bolognesi C, et al. Pleural malignant mesothelioma, genetic susceptibility and asbestos exposure. Mutat Res 2005; 592: 36-44. 10.1016/j.mrfmmm.2005.06.003NeriMFilibertiRTaioliEGarteSParacchiniVBolognesiCPleural malignant mesothelioma, genetic susceptibility and asbestos exposureMutat Res2005592364410.1016/j.mrfmmm.2005.06.00315993904Open DOISearch in Google Scholar
Franko A, Dolžan V, Arnerić N, Dodič-Fikfak M. The influence of gene-gene and gene-environment interactions on the risk of asbestosis. Biomed Res Int 2013; 2013: 405743. 10.1155/2013/405743FrankoADolžanVArnerićNDodič-FikfakM.The influence of gene-gene and gene-environment interactions on the risk of asbestosisBiomed Res Int2013201340574310.1155/2013/405743374190923984360Open DOISearch in Google Scholar
